Speaker See Mee Hoong2019-05-29T14:58:12+08:00

Plenary & Workshop Speakers

M.D (UPM), M S General Surgery (UM), Fellowship Breast Oncoplastic Surgery UM-Mahidol University (Thailand)

Associate Prof. Dr See Mee-Hoong is a lecturer and Oncoplastic Breast Surgeon at University Malaya Medical Center (UMMC). She obtained her undergraduate degree from University Putra Malaysia in 2003. Subsequently, she completed her Master Degree of Surgery (General) from University Malaya in May 2011. She joined University Malaya Medical Faculty in 2012 as a clinical lecturer (subspecializing in Breast Oncoplastic Surgery). Currently, she is a Oncoplastic Breast Surgeon in University Malaya Medical Centre and University Malaya Specialist Centre. She was an honorary fellow of Breast Oncoplastic Surgical Training in Siriraj Hospital, Mahidol University, Bangkok, Thailand in 2013.She is currently the investigator and co-investigator for a few clinical trials such as risk for breast cancer, Intraoperative Radiotherapy (TARGIT B Trial), improving outcome for breast conserving surgery and oncology treatment for Her-2 positive breast cancer (Samsung Trial). She is a member of College of Surgeon and Breast Chapter of Academy of Medicine Malaysia. Her fields of interest are breast oncoplastic surgery, minimally invasive breast surgery (Endoscopic), immediate and delayed breast and nipple reconstruction for breast cancer. She is also PI and has been collaborate with other researchers for local, national and international studies and grants.


Commentary: Is it time R-NSM justified for breast cancer operations?

R-NSM Is a new approach was first described in 2015 in Europe In September 2018 in New Jersey, USA and Robotic mastectomy, with immediate reconstruction, opens the door to a new era of mastectomy and a new outlook for patients who are candidates. However, it was called to hold as FDA following a patient had died of uterine cancer in US 2017 following a laparoscopic hysterectomy performed with a power morcellator (robotic) that resulted in the upstaging of an undetected gynecologic cancer. These has brought to the review and discussion of the use of R-NSM and certainly suitability and selection of subset how patients criteria and more clinical trials with longer outcome will be carried out to assess the oncological safety for the procedure.